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Malignant transformation of cells is associated with
downregulation of HLA class I APM components in
most of the tumors. These defects are clinically relevant,
since they are frequently associated with the clinical
course of the disease. Only in a few tumors malignancy is
associated with the upregulation of HLA class I antigens.
Among them is hepatocellular carcinoma (HCC). The
frequency of HLA class I APM component upregulation
and its clinical significance in HCC are not known. These
topics were investigated in the present study, since the
resulting information may contribute to assess the thera-
peutic efficacy of T cell-based immunotherapy for the
treatment of HCC. Twenty-one surgically resected
primary HCC tumors and autologous adjacent non-
malignant tissues were stained with a unique panel of
monoclonal antibodies which recognize HLA class I
APM components. The staining patterns of the malig-
nant tumors were compared to those of the autologous
non malignant tissues. To assess the functional signifi-
cance of changes in HLA class I APM component
expression in HCC tumors, the results of immunohisto-
chemical staining were correlated with the extent of
CD8+ cytotoxic T-lymphocyte infiltrate, quantified with
a computer-aided image analysis system. In all the HCC
tumors, malignant hepatocytes expressed high levels of
HLA class I APM components. In contrast these mole-
cules were not detected in normal hepatocytes, although
they displayed a low expression in some apparently
normal hepatocytes adjacent to the HCC tumor. The
HLA class I APM component upregulation in HCC was
associated with the extent of CD8+ T cell infiltrate,
although this association did not reach the level of
statistical significance. Our results corroborate the infor-
mation in the literature about the lack of HLA class I
antigen expression in hepatocytes. Furthermore our
study shows for the first time that APM components are
also not detectable in normal hepatocytes. Lastly our
study shows that HLA class I APM component upregula-
tion is very frequent in HCC. Its association with T cell
infiltrate, although not statistically significant, is compati-
ble with the possibility that HCC cells are recognized by
CD8+ T cells. If so, HCC should represent an attractive
target to apply T cell-based immunotherapy.
Authors’ details
1Laboratory of Molecular Gastroenterology, Humanitas Clinical and Research
Center, Rozzano, Italy.
2Laboratory of Quantitative Medicine, Humanitas
Clinical and Research Center, Rozzano, Italy.
3Department of Pathology,
Humanitas Clinical and Research Center, Rozzano, Italy.
4Department of
Internal Medicine, Texas Tech University Health Science Center Medical
School, Lubbock, TX, USA.
5Department of Surgery, Massachusetts General
Hospital, Harvard Medical School, Boston, MA, USA.
Published: 7 November 2013
doi:10.1186/2051-1426-1-S1-P264
Cite this article as: Grizzi et al.: High frequency of HLA class I antigen
processing machinery (APM) component upregulation in primary
hepatocellular carcinoma tumors. Journal for ImmunoTherapy of Cancer
2013 1(Suppl 1):P264.
1Laboratory of Molecular Gastroenterology, Humanitas Clinical and Research
Center, Rozzano, Italy
Full list of author information is available at the end of the article
Grizzi et al. Journal for ImmunoTherapy of Cancer 2013, 1(Suppl 1):P264
http://www.immunotherapyofcancer.org/content/1/S1/P264
© 2013 Grizzi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.